ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Durable tracking anti-SARS-CoV-2 antibodies in cancer patients recovered from COVID-19

Huang, Yongsheng; Yu, Jing; Li, Dan; He, Kai; Liu, Wenyang; Wang, Lin; Chen, Yeshan*; Xie, Conghua*; Wu, Xiaowei*华中科技大学; 南方医科大学; 武汉大学; 中国医学科学院; 中国医学科学院北京协和医院
Scientific Reports2021-8-30DOI: 10.1038/s41598-021-96195-w
3阅读
引用收藏
分享

摘要

Cancer patients are more susceptible to SARS-CoV-2 infection and generally have higher mortality rate. Anti-SARS-CoV-2 IgG is an important consideration for the patients in this COVID-19 pandemic. Recent researches suggested the rapid decay of anti-SARS-CoV-2 antibodies in the general population, but the decline rate of the antibodies in cancer patients was unknown. In this observational study, we reported the clinical features of the 53 cancer patients infected by SARS-CoV-2 from Wuhan, China and tracked the presence of anti-SARS-CoV-2 antibodies in the patients for more than 12 months. We found the duration (days) of anti-SARS-CoV-2 IgG in the patients was significant longer in chemotherapy (mean: 175; range: 75 to 315) and radiotherapy groups (mean: 168; range: 85 to 265) than in non-chemo- or radio-therapy group (mean: 58; range: 21 to 123) after their recovery from COVID-19. We also used single-cell RNA sequencing to track the immunologic changes in a representative patient recovered from COVID-19 and found that CD8 + effective T cells, memory B cells and plasma cells were persistently activated in the patient undergoing chemotherapy. Together, our findings show that chemotherapy and radiotherapy might be beneficial to extend the duration of anti-SARS-CoV-2 IgG.

相关
加载中…
  • Impact of chemotherapy and immunotherapy on the composition and function of immune cells in COVID-19 convalescent with gynecological tumors
    Qin, Tianyu; Guo, Ensong; Lu, Funian; Fu, Yu; Liu, Si; Xiao, Rourou; Wu, Xue; Liu, Chen; He, Chao; Wang, Zizhuo; Qin, Xu; Hu, Dianxing; You, Lixin; Li, Fuxia; Li, Xi; Huang, Xiaoyuan; Ma, Ding; Xu, Xiaoyan; Yang, Bin*; Fan, Junpeng*Aging-US, 2021, 13(23): 24943-24962.被引 2
  • Association of COVID-19 and Lung Cancer: Short-Term and Long-Term Interactions
    Peng, Ying-Long; Wang, Zi-Yan; Zhong, Ri-Wei; Mei, Shi-Qi; Liu, Jia-Qi; Tang, Li-Bo; Guo, Zhi; Ren, Zi-Rui; Wu, Lv; Deng, Yu; Chen, Zhi-Hong; Zhou, Qing; Xu, Chong-Rui*Cancers, 2024, 16(2): 304.
  • Impaired serological response to COVID-19 vaccination following anticancer therapy: A systematic review and meta-analysis
    Tang, Kefu*; Wei, Zhiying; Wu, Xi*Journal of Medical Virology, 2022, 94(10): 4860-4868.被引 10
查看全部 →

发表信息

论文状态
公开发表
期刊
Scientific Reports
发表日期
2021-08-30
卷期
第 11 卷, 第 1 期
页码
17381
DOI
10.1038/s41598-021-96195-w
语言
ENGLISH
期刊收录
NSL
期刊等级
3区
成果收录
SCIE
资助标注
Ministry of Science and Technology of the People's Republic of China [2016YFC1302203]; Natural Science Foundation of Hubei Province [2020CFB740]

作者

  • H

    Huang, Yongsheng (第一作者)

    chinese acad med sci · peking union med coll

  • Y

    Yu, Jing

    wuhan univ

查看全部 9 位作者收起作者
  • L

    Li, Dan

    chinese acad med sci · peking union med coll

  • H

    He, Kai

    southern med univ

  • L

    Liu, Wenyang

    chinese acad med sci · peking union med coll

  • W

    Wang, Lin

    chinese acad med sci · peking union med coll

  • C

    Chen, Yeshan (通讯)

    huazhong univ sci & technol

  • X

    Xie, Conghua (通讯)

    wuhan univ

  • W

    Wu, Xiaowei (通讯)

    huazhong univ sci & technol

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417